Mediwound Stock Price, News & Analysis

MediWound (Nasdaq: MDWD) has published new Phase II data analysis for EscharEx® in the treatment of venous leg ulcers (VLUs) in Advances in Wound Care journal. The study, analyzing 119 VLU patients, demonstrated a significant correlation between wound bed preparation (WBP) and wound closure.

Key findings revealed that wounds achieving WBP were 4.1 times more likely to close compared to those that did not (p = 0.0004). Notably, wounds failing to achieve WBP had a 90% probability of not healing. Early WBP achievement (within 14 days) showed a significantly increased healing likelihood (Relative Risk = 2.4). The study validates EscharEx's potential in accelerating wound bed preparation for improved healing outcomes.

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, will release its Q2 2025 financial results on Thursday, August 14, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and provide corporate updates.

Investors can access the call via multiple channels including toll-free numbers for US and Israel, and an international dial-in. A webcast replay will be available in the Investors section of MediWound's website after the call.

MediWound (NASDAQ: MDWD) reported Q1 2025 financial results and provided corporate updates. The company generated $4.0 million in revenue for Q1 2025, down from $5.0 million in Q1 2024, and reported a net loss of $0.7 million ($0.07 per share). Key developments include: Their VALUE Phase III trial for EscharEx in venous leg ulcers is progressing with 216 patients across 40 sites in the U.S. and Europe. The company has secured collaborations with major wound care companies including Solventum, Mölnlycke, MIMEDX, and Kerecis. NexoBrid continues to gain traction with nearly 60 burn centers ordering the product, showing a 207% year-over-year increase in revenue. The company's new manufacturing facility expansion is on track for full operational capacity by end-2025, expected to increase production capacity sixfold. The company maintains a strong financial position with $38.7 million in cash and equivalents as of March 31, 2025, and reaffirmed its full-year 2025 revenue guidance of $24 million.

MediWound (NASDAQ: MDWD) published a post hoc analysis in Wounds journal comparing their EscharEx® treatment to SANTYL® for venous leg ulcers (VLUs). The analysis, based on Phase II ChronEx trial data, demonstrated superior clinical performance of EscharEx over SANTYL, the only FDA-cleared enzymatic debridement agent currently available.

Key findings showed that 63% of EscharEx patients achieved complete debridement at 2 weeks versus 0% in the SANTYL group. The median time to debridement was 9 days for EscharEx, while SANTYL did not achieve this milestone. Wound Bed Preparation was achieved by 50% of EscharEx patients in 2 weeks compared to 0% with SANTYL. Notably, wound closure rates were 33% for EscharEx versus 25% for SANTYL, with significantly faster mean time to closure (48 days vs. 76 days). Both treatments showed similar safety profiles, though deep wound infection rates were lower in the EscharEx group (11% vs. 38%).

MediWound Ltd. (NASDAQ: MDWD), a leader in enzymatic therapeutics for tissue repair, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 21, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time following the results release.

Investors can access the call through various channels including toll-free (1-844-676-8833), Israel (1-80-921-2373), and international (1-412-634-6869) numbers. A webcast replay will be available in the Investors section of MediWound's website after the call.

MediWound (Nasdaq: MDWD) announced plans to present 10 scientific abstracts at two major wound care conferences: the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2025 in Grapevine, Texas.

The presentations will showcase new data on EscharEx®, their investigational enzymatic therapy for chronic wounds. Key highlights include:

• New in vitro data demonstrating EscharEx's selective proteolytic activity
• Results showing superior debridement efficacy compared to SANTYL®
• Case studies on EscharEx's use in advanced diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs)
• Updates on the ongoing VALUE Phase III study

The VALUE Phase III study is actively enrolling VLU patients across multiple sites, building on positive results from three completed Phase II studies that demonstrated EscharEx's efficacy and safety in wound care.

MediWound (NASDAQ: MDWD) reported its Q4 and full-year 2024 financial results, achieving $20.2 million in annual revenue, up from $18.7 million in 2023. The company projects $24 million revenue for 2025.

Key developments include initiating the VALUE Phase III trial for EscharEx® in venous leg ulcers, expanding strategic collaborations with industry leaders including Kerecis, and securing €16.5 million in European Innovation Council funding. NexoBrid® showed strong momentum with U.S. hospital orders increasing 42% in Q4.

Financial highlights: Q4 revenue reached $5.8 million with a 15.5% gross margin. Full-year net loss was $30.2 million ($3.03 per share), significantly higher than 2023's $6.7 million loss, primarily due to warrant revaluation expenses. The company ended 2024 with $43.6 million in cash and secured $25 million through a strategic PIPE investment led by Mölnlycke Health Care.

MediWound (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, has scheduled its Fourth Quarter and Full Year 2024 financial results release for Wednesday, March 19, 2025. The company will host a conference call and live webcast at 8:30 a.m. Eastern Time on the same day to discuss the financial results and provide corporate updates.

MediWound (Nasdaq: MDWD) announced the publication of its Phase III Children Innovative Debridement Study (CIDS) in Burns, the peer-reviewed Journal of the International Society for Burn Injuries. The study evaluated NexoBrid® compared to standard of care in pediatric patients with deep thermal burns.

The publication, titled "Open-Label RCT of the Efficacy and Safety of NexoBrid Compared to SOC in Children with Burns," presents findings that supported NexoBrid's label expansion for pediatric patients in the E.U. (2023) and U.S. (2024). The results confirm NexoBrid's superiority as a rapid, effective, and non-surgical alternative for eschar removal in pediatric burn patients.

Professor Jose Ramón Martínez-Méndez noted that pediatric burn patients account for approximately 30% of all burn cases and present unique challenges. NexoBrid provides a non-surgical solution that effectively removes eschar while preserving healthy tissue, addressing the need to protect viable dermis and improve outcomes.